Establishment and validation of predictive models by mutational and transcriptional factors for the prognosis of stage IV colorectal cancer patients with liver metastasis who undergo palliative surgery on primary tumors.
{"title":"Establishment and validation of predictive models by mutational and transcriptional factors for the prognosis of stage IV colorectal cancer patients with liver metastasis who undergo palliative surgery on primary tumors.","authors":"Sijia Shen, Xu Zhang","doi":"10.21037/tcr-24-1183","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The prognostic factors at mutational and transcriptional levels are not clear for stage IV colorectal cancer (CRC) patients with liver metastasis who undergo primary cancer palliative surgery with post-surgical adjuvant therapy. We aimed to establish and validate models for predicting the prognosis of these patients by combining mutational, transcriptional and clinicopathological information.</p><p><strong>Methods: </strong>Data of 45 stage IV CRC patients with liver metastasis were downloaded from the cBioportal database as the training cohort. Another 30 patients from our hospital were retrospectively recruited as the external validation cohort. Patients were followed up to 4,699 days (median: 823 days) and 2,380 days (median: 980 days) for the overall survival (OS) in the training and validation cohort, respectively. Patients were followed up to 4,699 days (median: 264 days) and 2,259 days (median: 272 days) for the progression-free survival (PFS) in the training and validation cohort, respectively. Tissue samples of the primary CRC were collected and sequenced. Data were analyzed and figures were plotted using the R software.</p><p><strong>Results: </strong>The mutational and transcriptional alterations and their features were characterized. <i>APC</i>, <i>TP53</i>, <i>TTN</i>, <i>KRAS</i> and <i>SYNE1</i> were genes with the highest mutational frequency. Significantly upregulated and downregulated genes can be found in transcription. Age, <i>APC2</i> mutations, and <i>ADRB1,</i> <i>ASTL</i>, <i>MRPL23-AS1</i> and <i>PDZK1</i> transcription significantly stratified patient OS, while the <i>KRAS</i>, <i>PTPRF</i>, <i>FREM2</i>, and <i>CLOCK</i> mutations and <i>LY6H,</i> <i>TMEM163, RFX8, ARHDGDIG, TECTA</i> and <i>MYEOV</i> transcriptions significantly stratified patient PFS. Multivariate analyses identified age, <i>APC2</i> mutations and <i>ADRB1</i> transcription as independent risk factors for OS. <i>KRAS</i> and <i>PTPRF</i> mutations and <i>RFX8</i> and <i>MYEOV</i> transcriptions were independent risk factors for PFS. The above independent risk factors were used to establish prediction models for OS and PFS. For the OS model, the 1-, 3- and 5-year area under the curve (AUC) reached 0.858, 0.774 and 0.907 in internal validation, and reached 0.810, 0.778 and 0.924 in external validation, respectively. For the PFS model, the 6 months, 1-year and 1.5-year AUC reached 0.950, 0.803 and 0.847 in internal validation, and reached 0.919, 0.949 and 0.944 in external validation, respectively.</p><p><strong>Conclusions: </strong>The prognostic factors for stage IV CRC patients with liver metastasis were identified. Models for predicting the OS and PFS were successfully established and validated. The models may help to establish the personalized therapeutic strategies before treatment.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"225-239"},"PeriodicalIF":1.5000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833386/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1183","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The prognostic factors at mutational and transcriptional levels are not clear for stage IV colorectal cancer (CRC) patients with liver metastasis who undergo primary cancer palliative surgery with post-surgical adjuvant therapy. We aimed to establish and validate models for predicting the prognosis of these patients by combining mutational, transcriptional and clinicopathological information.
Methods: Data of 45 stage IV CRC patients with liver metastasis were downloaded from the cBioportal database as the training cohort. Another 30 patients from our hospital were retrospectively recruited as the external validation cohort. Patients were followed up to 4,699 days (median: 823 days) and 2,380 days (median: 980 days) for the overall survival (OS) in the training and validation cohort, respectively. Patients were followed up to 4,699 days (median: 264 days) and 2,259 days (median: 272 days) for the progression-free survival (PFS) in the training and validation cohort, respectively. Tissue samples of the primary CRC were collected and sequenced. Data were analyzed and figures were plotted using the R software.
Results: The mutational and transcriptional alterations and their features were characterized. APC, TP53, TTN, KRAS and SYNE1 were genes with the highest mutational frequency. Significantly upregulated and downregulated genes can be found in transcription. Age, APC2 mutations, and ADRB1,ASTL, MRPL23-AS1 and PDZK1 transcription significantly stratified patient OS, while the KRAS, PTPRF, FREM2, and CLOCK mutations and LY6H,TMEM163, RFX8, ARHDGDIG, TECTA and MYEOV transcriptions significantly stratified patient PFS. Multivariate analyses identified age, APC2 mutations and ADRB1 transcription as independent risk factors for OS. KRAS and PTPRF mutations and RFX8 and MYEOV transcriptions were independent risk factors for PFS. The above independent risk factors were used to establish prediction models for OS and PFS. For the OS model, the 1-, 3- and 5-year area under the curve (AUC) reached 0.858, 0.774 and 0.907 in internal validation, and reached 0.810, 0.778 and 0.924 in external validation, respectively. For the PFS model, the 6 months, 1-year and 1.5-year AUC reached 0.950, 0.803 and 0.847 in internal validation, and reached 0.919, 0.949 and 0.944 in external validation, respectively.
Conclusions: The prognostic factors for stage IV CRC patients with liver metastasis were identified. Models for predicting the OS and PFS were successfully established and validated. The models may help to establish the personalized therapeutic strategies before treatment.
期刊介绍:
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.